基于降低便秘副作用的碳酸钙D<sub>3</sub>咀嚼片制剂处方优化的研究<sup>*</sup>

doi:10.3969/j.issn.1671-7171.2024.07.002

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (750 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the optimal method of calcium carbonate D₃ chewable tablet formulation based on reducing side effects of constipation. 【Methods】The effects of different excipients on small intestine movement of mice were investigated by literature, and 5 commercially available products composed of different excipients were selected. According to the excipients composition of commercially available products, 2 kinds of finished products were made in the laboratory, and the optimal excipients composition was selected by mouse small intestine movement test. ICR mice were randomly divided into 8 groups according to body weight, namely blank control group, 401 self-made group, 601 self-made group, marketed product 1, 2, 3, 4 group and Jinbei commercial product group, with 20 mice (half male and half female) in each group. Single administration test (once administration) and repeated administration test (30 days administration) were conducted respectively. The dose of mice in each administration group was 130 mg/kg (measured by calcium), and the corresponding volume of pure water was given to the blank control group. The general clinical manifestations and fecal characteristics of mice were observed every day during the experiment. The fecal properties of mice in each experimental group were observed and photographed every week in the repeated administration test groups, and the fecal weight was measured within 6 hours. Intestinal propulsion test was performed after the last administration in both single administration test and repeated administration test to calculate the intestinal ink propulsion rate of mice. 【Results】Single administration of Calcium carbonate and vitamin D₃ chewable tablets composed of different excipients had no significant effect on small intestinal propulsion rate in mice. After repeated administration for 30 days, compared with the blank control group, fecal dryness was observed in mice in 601 self-made group, marketed product 1, 2, 3, 4 group, and the ink advancing rate was significantly reduced(P<0.05). The fecal weight of mice treated with 3 weeks and 4 weeks in 601 self-made group, marketed product 3, 4 group, and the fecal weight of mice treated with 4 weeks in marketed product 1, 2 group were significantly reduced(P<0.05); There were no significant effects on fecal traits, intestinal propulsion rate and fecal weight in 401 self-made group and Jinbei brand market group. 【Conclusion】Calcium carbonate and vitamin D₃ chewable tablets containing defecation promoting components can reduce constipation side effects caused by repeated administration, and excipients with different defecation promoting mechanisms can play a synergistic role. Through comparison in this study, Jinbei brand Calcium carbonate and vitamin D3 chewable tablets (Ⅱ) (patent No.ZL 2021 1 0357997.6), which is owned by Zhejiang Huanling Pharmaceutical Technology Co., Ltd., has the best prescription process. It can effectively reduce the side effect of constipation caused by repeated administration.

Key words： Constipation Calcium Carbonate Pharmaceutical Preparations

Received: 01 July 2024

PACS:

R442.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2024.07.002 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2024/V41/I7/964

[1] CORMICK G, BELIZÁN J M. Calcium intake and health[J].Nutrients,2019,11(7):1606.
[2] WANG J W, TAO S, JIN X Y, et al. Calcium supplement by tetracycline guided amorphous calcium carbonate potentiates osteoblast promotion for synergetic osteoporosis therapy[J].Theranostics,2020, 10(19):8591-8605.
[3] WASILEWSKI G B, VERVLOET M G, SCHURGERS L J.The Bone-vasculature axis: calcium supplementation and the role of Vitamin K[J].Front Cardiovasc Med,2019, 6:6.
[4] 孙晨,马力.全科临床诊疗思维系列:便秘[J].临床药物治疗杂志,2021,19(5):72-76.
[5] 蓝胜,张卫锋,吕华萍,等.中药百立停提取物对小鼠腹泻和小肠运动功能的影响[J].养猪,2021(4):96-97.
[6] 齐丽娟,林子君,佟娜,等.2种小鼠便秘模型的比较研究[J].毒理学杂志,2021,35(5):395-400.
[7] 杨夕缘.动物双歧杆菌乳亚种干预便秘的作用途径研究[D].江苏:江南大学,2023.
[8] 苏立杰,李国坤,陈淼焕,等.芹菜素对慢传输型便秘小鼠的通便作用[J].现代食品科技,2022,38(6):20-27.
[9] 李晓东.夏黄颗粒治疗阿片类药物所致便秘的临床观察和机制探讨[D].天津:天津中医药大学,2020.
[10] 姬妍茹,张正海,杨庆丽,等.黑菊芋水提液对便秘小鼠润肠通便作用的研究[J].食品工业科技,2020,41(20):319-323.
[11] 张中兰.甘露醇在内科疾病治疗中的应用体会[J].临床医药文献电子杂志,2015,2(22):4610-4611.
[12] 张石革,徐小薇,郝红兵.便秘与缓泻药[J].中国药房,2001,12(10):61-62.
[13] 唐尧,李志铭,谭建三,等.乳糖对肠钙吸收促进作用的探讨[J].中国药房,1997,7(6):274.
[14] 朱晓霞,汪国英,朱贤英.钙的作用机理及如何安全补钙的研究现状[J].保健医学研究与实践,2014,11(1):91-94.
[15] 王默涵,雷蕾,王俊,等. 人体的钙吸收与钙营养状况评价[J].现代食品,2020,12(24):25-30.
[16] 张方. 炎症性肠病患者血清钙、磷和胆固醇变化及临床意义[D]. 河南:郑州大学,2020.
[17] 李朋,韦伟. 重视非骨型肾型原发性甲状旁腺功能亢进症的诊断和治疗[J].临床外科杂志,2023,31(3):213-215.
[18] 朱秋漪,缪玉婵.绝经后骨质疏松症患者补钙认知情况调查及影响因素分析[J].中国妇幼保健,2023,38(17):3309-3312.
[19] 赖燕华.孕期监督补钙对预防妊娠期高血压疾病的效果及改善不良妊娠结局发生率的影响[J].智慧健康,2022,8(20):119-122.
[20] 杨惠莹.围绝经期及绝经后女性骨现状调查及骨质疏松风险评估模型构建[D]. 银川:宁夏医科大学,2022.
[21] 吴劲风.钙剂对未成年健康人群骨密度影响的Meta分析[J].中华关节外科杂志(电子版),2018,12(3):368-373.
[22] 樊利群.儿童常用补钙药物的合理选择[J].临床合理用药,2023,16(6):179-181.
[23] 刘旭亮,郝占西,李瑶,等.益生元对机体钙吸收及骨健康调节作用的研究进展[J].现代预防医学,2022,49(6):1036-1042.

[1]	. [J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(7): 1110-1112.